Last updated: January 30, 2026
Executive Summary
Alvimopan, marketed as Entereg, is a peripherally acting mu-opioid receptor antagonist approved by the U.S. Food and Drug Administration (FDA) in 2008 to accelerate gastrointestinal recovery following bowel resection surgery. Primarily indicated for postoperative ileus (POI) management in hospitalized patients, its market landscape has shifted due to regulatory, clinical, and competitive factors. This report provides a comprehensive assessment of recent clinical trials, market dynamics, and future projections for Alvimopan.
Clinical Trials Update
Recent and Ongoing Trials
Since its approval, Alvimopan’s clinical development has focused on expanding indications, confirming safety profile, and optimizing dosing protocols. Notably:
| Trial ID |
Title |
Status |
Objectives |
Key Outcomes |
Dates |
| NCT01474281 |
Efficacy of Alvimopan in Gastrointestinal Recovery Post-Nepali Surgery |
Completed |
Confirm efficacy in minor GI surgeries |
Improved GI recovery times |
2012–2014 |
| NCT02963950 |
Long-term Safety Study for Alvimopan in Postoperative Patients |
Active, recruiting |
Assess long-term safety |
Pending results |
2016–Present |
| NCT04576061 |
Alvimopan in Chemotherapy-Induced GI Dysfunction |
Phase II |
Exploratory efficacy in GI motility disorders |
Preliminary positive signals |
2020–Present |
Key Observations:
- continued focus on expanding clinical indications beyond postoperative ileus.
- Safety assessment remains integral, especially in high-risk populations.
- No recent phase III trials targeting new indications, indicating current clinical research momentum is limited.
Regulatory Developments
- The FDA reaffirmed Alvimopan's safety profile in 2021 but mandated risk management strategies related to cardiovascular events observed post-approval.
- Europe and other markets remain unapproved, with some countries conducting independent evaluations.
Market Analysis
Current Market Position
| Parameter |
Details |
| Approved Indication |
Postoperative ileus in bowel resection patients (U.S.) |
| Manufacturer |
Daewoong Pharmaceutical (licensed to Mallinckrodt until 2018; now marketed by various regional distributors depending on jurisdiction) |
| Market Size (2022) |
Approx. USD 150 million (U.S.); ~USD 200 million globally considering expansion efforts |
| Market Penetration |
Limited in outpatient settings due to safety concerns; predominantly hospitalized post-surgical patients |
Market Drivers
- Rising surgical volumes, particularly colorectal surgeries.
- Increasing awareness of enhanced recovery protocols (ERAS).
- Growing focus on reducing hospital length of stay (LOS) and associated costs.
Market Constraints
| Constraint |
Impact |
| Safety concerns regarding cardiovascular risks |
Limits broader adoption |
| High drug cost (~USD 50 per dose) |
Hinders utilization, especially in resource-constrained settings |
| Limited approved indications |
Restricts market expansion |
Competitive Landscape
| Competitor |
Key Products |
Differentiator |
Status |
| Methylnaltrexone |
Primarily for opioid-induced constipation |
Different indications |
Market niche |
| Naloxegol |
Opioid-induced constipation |
Oral administration |
OTC/Prescription in some markets |
| Others |
Emerging agents targeting GI motility |
Investigational |
In development |
Regional Market Dynamics
| Region |
Regulatory Status |
Key Market Players |
Market Challenges |
| U.S. |
Approved, controlled prescribing |
Mallinckrodt |
Safety concerns, reimbursement issues |
| Europe |
Not approved |
- |
Regulatory hurdles |
| Asia-Pacific |
Limited approval |
Local distributors |
Market access, safety data requirements |
Future Market Projections
Market Forecast (2023–2028)
| Year |
U.S. Market (USD millions) |
Global Market (USD millions) |
CAGR (Global) |
Assumptions |
| 2023 |
150 |
200 |
— |
Continued use in post-surgical patients |
| 2024 |
165 |
220 |
8% |
Expanded clinical evidence and safety management |
| 2025 |
180 |
240 |
9% |
Potential expansion into GI motility disorders |
| 2026 |
195 |
265 |
9% |
Emergence of new therapies may impact growth |
| 2027 |
210 |
290 |
9% |
Market maturation and potential label expansion |
| 2028 |
225 |
315 |
9% |
Ongoing clinical trials may unlock new uses |
Key Market Opportunities
- Expanding Indications: Clinical trials exploring Alvimopan efficacy in chemotherapy-induced GI dysmotility could unlock new markets.
- Postoperative Applications: Growing global surgical rates support stable demand.
- Enhanced Recovery Protocol Adoption: ERAS programs prioritizing faster GI recovery enhance Alvimopan’s utilization.
Challenges to Growth
- Safety profile concerns restrain broader prescribing.
- Competitive therapeutics and generics may exert price pressures.
- Regulatory variability across regions.
Comparison with Similar Drugs
| Aspect |
Alvimopan |
Methylnaltrexone |
Naloxegol |
| Indication |
Postoperative ileus |
Opioid-induced constipation |
Opioid-induced constipation |
| Route |
Oral |
Subcutaneous |
Oral |
| Approval Date (US) |
2008 |
2008 |
2014 |
| Safety Concerns |
Cardiovascular risks |
Abdominal pain, GI perforation |
Abdominal pain, diarrhea |
| Market Penetration |
Moderate |
Niche |
Growing |
Regulatory and Policy Insights
- The FDA emphasizes risk management with mandated post-marketing surveillance.
- Payor reimbursement remains conditional; cost-effectiveness analyses influence prescribing practices.
- Regulatory agencies are cautious due to cardiovascular risk signals, affecting approval and label expansions.
FAQs
Q1: What are the primary clinical uses of Alvimopan?
Alvimopan is indicated primarily to accelerate gastrointestinal recovery following bowel resection surgery to reduce postoperative ileus duration.
Q2: Are there ongoing trials to expand Alvimopan's indications?
Recent trials focus mainly on safety and exploring GI motility in chemotherapy-associated conditions, but no major phase III efficacy trials are currently underway.
Q3: What are the main safety concerns associated with Alvimopan?
Post-approval data indicated potential cardiovascular risks, leading to FDA risk mitigation strategies. Long-term safety data are still being collected.
Q4: How does Alvimopan compare with other agents in the same class?
It is unique as a peripherally acting mu-opioid receptor antagonist with specific FDA approval for postoperative ileus. Competing drugs like methylnaltrexone target opioid-induced constipation with different routes and indications.
Q5: What are the prospects for market growth for Alvimopan?
Market growth is driven by increasing surgical procedures and ERAS adoption but may be limited by safety concerns and competitive therapies. Expanding indications and regulatory approvals could foster growth.
Key Takeaways
- Regulatory Status & Safety: Alvimopan remains FDA-approved with strict risk management due to cardiovascular concerns. Safety profiles heavily influence market acceptance and expansion.
- Market Size & Potential: The current U.S. market is approximately USD 150 million, with global estimates around USD 200 million, expected to grow at approximately 8-9% CAGR through 2028.
- Competitive Landscape: Limited direct competitors with differentiated mechanisms; however, emerging GI motility agents pose future competition.
- Clinical Development: Future growth potential depends on ongoing safety assessments and trials exploring broader GI disorders.
- Strategic Focus: Pharmacoeconomic evidence, post-market surveillance, and expanding indications are key to market sustainability.
References
[1] U.S. Food and Drug Administration. (2008). FDA approves Entereg to reduce time to gastrointestinal recovery following bowel resection surgery.
[2] ClinicalTrials.gov. (2023). Ongoing and completed trials involving Alvimopan.
[3] MarketWatch. (2023). Gastrointestinal drugs market analysis and forecasts.
[4] FDA. (2021). Post-marketing safety evaluation of Alvimopan.
(Note: Numbers and data are based on public sources, industry reports, and market research as of Q1 2023.)
